We are live on ! Find out more
NEXI

NexImmune, Inc. Common Stock
NEXI

Delisted

NEXI was delisted on the 11th of July, 2024.

Back to rankings

29 hedge funds and large institutions have $1.45M invested in NexImmune, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

24% less funds holding

Funds holding: 38 → 29 (-9)

67% less capital invested

Capital invested by funds: $4.34M → $1.45M (-$2.89M)

69% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 13

Holders
29
Holders Change
-9
Holders Change %
-23.68%
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
7
Reduced
4
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$462K
2
Millennium Management
Millennium Management
New York
+$172K
3
Renaissance Technologies
Renaissance Technologies
New York
+$138K
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$27.7K
5
VF
Virtu Financial
New York
+$21.3K

Top Sellers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
-$513K
2
ACH
ArrowMark Colorado Holdings
Colorado
-$478K
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$291K
4
BM
Bridger Management
New York
-$222K
5
KHCM
Kettle Hill Capital Management
New York
-$206K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$199 -$1.3K -104 -76%
Wells Fargo
27
Wells Fargo
California
$30 +$12 +1 +25%
Bank of America
28
Bank of America
North Carolina
$12 +$25 +2 New
SPC
29
Slate Path Capital
New York
– -$513K -37,000 Closed
Fidelity Investments
30
Fidelity Investments
Massachusetts
– -$291K -21,000 Closed
BM
31
Bridger Management
New York
– -$222K -16,000 Closed
KHCM
32
Kettle Hill Capital Management
New York
– -$206K -14,828 Closed
BBHC
33
Brown Brothers Harriman & Co
New York
– -$68K -4,915 Closed
6CM
34
683 Capital Management
New York
– -$56K -4,027 Closed
SEI Investments
35
SEI Investments
Pennsylvania
– -$21K -1,550 Closed
Rockefeller Capital Management
36
Rockefeller Capital Management
New York
– -$15K -1,114 Closed
Man Group
37
Man Group
United Kingdom
– -$11K -813 Closed
Qube Research & Technologies (QRT)
38
Qube Research & Technologies (QRT)
United Kingdom
– -$8K -562 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$8K -560 Closed
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
– -$748 -54 Closed
Osaic Holdings
41
Osaic Holdings
Arizona
– +$50 +4 +67%
1
2

NEXI Hedge Fund Activity: Q4 2022 in Review

29 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in NexImmune, Inc. Common Stock (NEXI) for Q4 2022, worth a combined $1.45M — down 67% from $4.34M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NEXI and 4 opened new positions — a net loss of 9 holders — while 4 trimmed existing stakes and 7 added.

The largest buyer was Goldman Sachs, opening a new position worth an estimated $462K. The largest seller was Slate Path Capital, exiting entirely with an estimated $513K sold.

  • 29 institutional investors held NexImmune, Inc. Common Stock (NEXI) as of Q4 2022, down from 38 in Q3 2022.
  • Funds reported $1.45M of NexImmune, Inc. Common Stock stock for Q4 2022, down 67% quarter-over-quarter.
  • 4 funds opened new NexImmune, Inc. Common Stock positions in Q4 2022 and 13 closed out, a net change of -9 holders.
  • The largest NexImmune, Inc. Common Stock buyer in Q4 2022 was Goldman Sachs, an estimated $462K added.
  • The largest NexImmune, Inc. Common Stock seller in Q4 2022 was Slate Path Capital, an estimated $513K sold.

Based on aggregated 13F filings for Q4 2022.